Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings Gan & Lee Pharmaceuticals.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Gan & Lee Pharmaceuticals.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses: Gan & Lee Pharmaceuticals.
  • The company does not generate enough profits, which is an alarming weak point.
  • With a 2026 P/E ratio at 25.2 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.

Rating Financials

Gan & Lee Pharmaceuticals. SectorChina

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

-

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

More ratings

Rating Valuation

Gan & Lee Pharmaceuticals. SectorChina

Global Valuation

-

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

-

P/E

PBR

-

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Gan & Lee Pharmaceuticals. SectorChina

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Gan & Lee Pharmaceuticals. SectorChina

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

Gan & Lee Pharmaceuticals. SectorChina

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
5.27B - -
72.52B
BBB
52.9B
AA
45.93B
BBB
35.49B
A
29.22B
AA
20.98B -
BBB
- -
19.56B
AAA
20.04B
AA
16.66B
AA
Average 31.86B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. 603087 Stock
  4. Ratings Gan & Lee Pharmaceuticals.